HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor
Dr. Busch will help the Company to further advance the development of MKK4 inhibition, a first-in-class treatment paradigm for liver resection and transplant.
Dr. Busch will help the Company to further advance the development of MKK4 inhibition, a first-in-class treatment paradigm for liver resection and transplant.
HRX-0215 proved to be safe and well tolerated in healthy volunteers.
He follows Dr. Graham Dixon who served as Chairman on the Board of HeparegeniX since 2017.
New data supporting therapeutic potential of MKK4 inhibition in advanced liver diseases.
HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination therapy.
HRX-0215 is the first compound from the company´s small molecule-based drug discovery platform ready for clinical testing.
New preclinical data indicate beneficial therapeutic effects in non-alcoholic steatohepatitis (NASH)-associated liver carcinomas.
30 years of specialist knowledge in clinical operations to translate encouraging preclinical results into the clinic.
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...